Background: Epilepsy is one of the most common neurological disorders, affecting about 1% of the world's population. The currently available anticonvulsants are effective in reducing the severity and number of seizures in less than 70% of patients. Moreover, their usage is associated with undesirable side effects ranging from cosmetic (gingival hyperplasia) to life threatening (hepatotoxicity, megaloblastic anemia). Therefore, the continued search for the safer and more effective antiepileptic drugs is urgently necessary. Literature survey reveals that various derivatives of quinazolinone, thienopyrimidine and pyridopyrimidine shown very promising anticonvulsant activity along with other pharmacological activities. So we concentrate our aim to screen novel quinazolinone fused with thienopyrimidine/pyridopyrimidine.
Recently a great number of fused pyrimidine derivatives became known as potential drug molecules against various types of diseases. One of the most important compound families are quinazolinones. The quinazolinone moiety is a building block for approximately 150 naturally occurring alkaloids and drugs [7] . Literature survey reveals that natural quinazolinones and their synthetic analogs possess a variety of pharmacological activities, including PDE inhibitory activity [8] [9] [10] [11] [12] , anticonvulsant [5, 6] , bronchodilator [13] , anti-inflammatory [14, 15] , antimalarial [16] , antituberculous [17] , anti-HIV [18] , narcotic antagonist [19] , anti-tumor [20] , tyrosine kinase inhibitor [21] , adenosine antagonist [22] , antimicrobial [14] , etc. Similarly thienopyrimidine [23, 24] and pyridopyrimidine [25] , the bioisosters of quinazolinones are known to possess good anticonvulsant activity.
We are especially interested in developing novel quinazolinones fused with various heterocycles at 2 and 3 positions. Previously we have reported synthesis and pharmacological evaluation of various quinazolinone derivatives [5, 11, 14, [26] [27] [28] . In previous report [5] we have described the number of quinazolinones and their possible anticonvulsant activity. These compounds (see Figure 1 ) have some sort of similarity with the well known methaqualone.
These compounds showed a very promising anticonvulsant activity with less neurotoxicity.
Among the twenty six compounds tested, the compound 2-phenyl-3-(4-methoxybenzothiazol-2- While searching for anticonvulsant compound, we have found that quinazolinone ring is one of the moieties on which studies have been concentrated [14] . Thienopyrimidine and pyridopyrimidine are also bioisosters of quinazolinone, and anticonvulsant activity have been extensively investigated and performed. All of these have made us think that thienopyrimidine/pyridopyrimidine fused quinazolinones are promising compounds for finding a drug with anticonvulsant action.
In spite of the fact that according to the literature thousands of quinazolinones, thienopyrimidine and pyridopyrimidine related compounds have been synthesized and tested for a possible central nervous system depressant and anticonvulsant activity, no attempt has been made to incorporate the thienopyrimidine/pyridopyrimidine moiety and the quinazolinone nucleus in a single molecular framework. So we attempted to synthesize various analogues of 7H-thieno [2',3':4,5] [26, 27] .
Pharmacology
Continuing our studies on quinazolinones heterocycles [5, 11, 14, [26] [27] [28] that are attractive candidates [5] as anticonvulsant agents, we have designed a novel thienopyrimidine fused quinazolinones and pyridopyrimidine fused quinazolinones. In the pharmacological study, we have investigated anticonvulsant activity as well as the neurotoxicity.
The pre-clinical discovery and development of new chemical agents for the treatment of epilepsy are based mainly on the use of predictable animal models, from which the MES and scPTZ screens are recognized as the ''gold standards'' in the early stages of testing [29] .
Initial anticonvulsant activity and neurotoxicity (NT) data for the thienopyrimidine/pyridopyrimidine fused quinazolinones 1-36 are given in Table 1 and most of the compounds showed remarkable anticonvulsant activity. The title compounds revealed diversified anticonvulsant properties.
The MES model has served to identify currently available anticonvulsants that are functionally similar to phenytoin, and most of these compounds display in common the ability to inactivate voltage-dependent Na + channels in a use-dependent fashion. Activity in this model seems highly predictive of the ability of those currently available anticonvulsants to protect against partial and secondarily generalized tonic-clonic seizures. The scPTZ model has proven to be a good predictor of clinical efficacy against generalized spike-wave epilepsies of the absence type. Thus, the MES and scPTZ screens have become the most widely employed seizure models for early identification of candidate anticonvulsants.
The Anti-MES and Anti-scPTZ (ED50 values in Tables 1) indicated significant anticonvulsant activity for the tested compounds 1-15 and 16-36. However, they were found to be less potent when compared with the reference standard phenytoin (ED50 value in MES model 6.48 at t=0.5h and 7.1 at t = 4h) and Phenobarbital (ED50 value in MES model 16.8 at t=0.5h and 21.8 at t = 4h; ED50 value in scPTZ model 11.5 at t=0.5h and 13.2 at t = 4h). The different substituent at the aromatic ring and heterocycles exerts a significant influence on the biological activity by modulating the lipophilicity and thereby facilitating penetration across the bloodbrain barrier. The presence of electron withdrawing groups (Bromo) at the quinazoline nucleus in general increases the potency of the tested compounds compared to compounds having no bromo group. In general dibromo substituted compounds are more potent than the monobromo and than non bromo compounds. This is because of the increased lipophilicity, which in turn increases the permeability across biological membrane. In general, among all the compounds evaluated, pyridopyrimidine (dibromo substituted) fused quinazolinones are more potent than thienopyrimidine (dibromo substituted) fused quinazolinones. Further it has been found that the ED50 andTD50 values of the tested compounds increase significantly at t = 4 h, compared to t = 0.5 h, in contrast to the reference compound, indicating that the tested compounds were metabolized with time in the biological environment. This trend was found to be more pronounced in compounds having electron withdrawing substituent on the ring compared to electron releasing substituent. To confirm this phenomenon in vivo, it will be necessary to carry out a kinetic study in an animal model. Based upon the results, it will also be necessary to optimize the lead compound by substituting a series of electron withdrawing groups at the aromatic ring and selectively modifying the quinazoline nucleus. The protection index (PI) values are found to be more significant for determining the relation between lipophilicity and toxicity. Tables 1 show that PI values were found for more potent compounds in contrast to less lipophilic compounds. Thus, as the lipophilicity increases, so does the toxicity and therefore also the protection index (PI). Among the compounds tested, 10,12-dibromo-1-(4-chloro-phenyl)-3- at t = 4h; ED50 value in scPTZ model 33.9 at t=0.5h and 37.2 at t = 4h; TD50 value 97.9 at t=0.5h and 122.7 at t = 4h;PI 2.854227 in MES and 2.887906 in scPTZ ).
SAR studies of 1,3,10,12-tetrasubstituted-8H-pyrido[2',3':4,5]pyrimido[6,1-b]quinazolin-8-ones 16-36.
Structure activity relationship (SAR) studies in this series indicated that the R 1 and R 2 substituent over the pyridine ring, exerted varied anticonvulsant activity. It has been found that anticonvulsant activity increases as R 2 = electron releasing groups, whereas if R 2 = electron withdrawing groups, then it decreases the activity. The compound with R 1 = electron releasing groups was showed more anticonvulsant activity than the compounds with R 1 = electron withdrawing groups. Among all the compounds in this series, 10,12-dibromo-1-(4-chloro- 
Attempted correlation of anticonvulsant activity with C log P data
To be effective as antiepileptic agents, antiepileptic drugs have to cross the blood brain barrier (BBB) [30] . Entry into the brain is therefore a crucial step in developing effective drug therapies for cerebral disorders. In vitro determination of brain-blood partitioning is difficult, time-consuming, expensive and not suitable to screen a large collection of chemicals. Therefore, we used alternative method based on computerized models. Lipophilic substances are able to permeate into the brain interstitium in a relatively easy way [31, 32] . First, we calculated the C log P value for each compound in order to reflect the overall lipophilicity of the thienopyrimidine/pyridopyrimidine fused quinazolinones (Table 1) . It is postulated that a C Log P value of at least 2.0 is required to cross the BBB [33, 34] .
The C log P data for all novel anticonvulsant compounds (1-15 & 16-36) were mentioned in Table 1 and ranged from 7.89724 to 2.89725. All the compounds have C Log P value above 2 which is required for effective penetration in the brain. As such no significant correlation could be established between C log P values and anticonvulsant activity of the title compounds. In general it was found that compounds having more C Log P values having less TD50 value. Table   1 shows that compounds with a weak C log P (compound 5) are able to protect the mice against convulsions but shown the least activity among all the compounds. Compounds 29 and 25 share an optimal C log P value and exhibit also an optimal anticonvulsant effect. In general, it was found that the correlation between the C log P and the in vivo anticonvulsant activity is not really straightforward. A Pentium IV Core 2 Duo computer (with 4GB RAM) with Windows Vista operating system was used. The calculated partition coefficient (C Log P) values were determined by using ChemDraw Ultra, computer software by CambridgeSoft.com.
Experimental

Anticonvulsant activity
Anticonvulsant activity of the title compounds (1-36) was evaluated by MES and scPTZ and Rotorod test for neurological toxicity (NT). Male albino mice were used as experimental animals.
The MES were induced by electroconvulsometer (Techno Instruments, Lucknow), using a technique described earlier [35] . The animals were subjected to electroshock (60 mA/0.2 s) via the transauricular electrodes. Further the compounds were evaluated against scPTZ model in mice. The anticonvulsant effect was assessed by recording the Tonic Hind-limb Extension at various dose levels at t = 0.5 and 4 h. Absence of seizure component like hind limb tonic extension with drug treatment was considered to be evidence of protection. Medium effective dose (ED50) was calculated for each compound and is presented in Tables 1. Acute neurotoxicity of all the test compounds was assessed in mice using the method described by Dunham and Miya [36] . Briefly, group of animals (mice) were trained to balance on a rotating rod (3 cm diameter and 6 rpm speed) and they were allowed three attempts to remain on the rotating rod for 20 s. Such trained animals were treated with the tested compounds at a various dose levels between 40-170 mg/Kg body weight by intraperitoneal administration. The tested compounds were considered to be neurotoxic at a particular dose level if the trained animal showed lack of Rolling Roller Performance. Each of the trained animals was tested in this manner at 30 min and 4 h after the drug administration, and the neurotoxic effect was recorded in terms of TD50. Based upon these results PI values were calculated as shown in Tables 1.
Theoretical C Log P calculation
The chemical structure of the molecules was drawn by the ChemDraw Ultra software.
The theoretical C Log P values of all the title compounds were calculated using ChemBioOffice.
Conclusion
In this paper, we have described the anticonvulsant activity of novel thienopyrimidine/pyridopyrimidine fused quinazolinone derivatives. The results obtained revealed that number of novel thienopyrimidine/pyridopyrimidine fused quinazolinone derivatives were effective in the MES and scPTZ screens, the most widely employed seizure models for early identification of candidate anticonvulsants. The most active was 10,12- Executive summary -In this study, attempts were made to design compounds that exhibit anticonvulsant activity.
Initially we designed these compounds considering the anticonvulsant potency of thienopyrimidine, pyridopyrimidine and quinazolinones. We observed that no attempt has been made to incorporate the thienopyrimidine/pyridopyrimidine moiety and the quinazolinone nucleus in a single molecular framework. So we attempted to synthesize compounds having thienopyrimidine/pyridopyrimidine and quinazolinone nucleus in a single frame work, in hope of good anticonvulsant activity.
From the study carried out on the title compounds, it was found that they exhibit good anticonvulsant activity with good protection index. Future perspective -As most of the compounds were shown a promising anticonvulsant activity with good protection, it will worthwhile if we develop this pharmacophore with help of computational tools. As these compounds have very good Clog P values, we are on the way to check out these compounds against neurodegenerative diseases. 
